VOYA Investment Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

VOYA Investment Management’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-151,085	Closed	-$3.05M	–	2839
2021 Q3	$3.05M	Sell	151,085 -3,274	-2%	-$90.4K	0.01%	997
2021 Q2	$5.76M	Sell	154,359 -33,895	-18%	-$1.04M	0.01%	818
2021 Q1	$4.81M	Sell	188,254 -26,139	-12%	-$668K	0.01%	851
2020 Q4	$4.72M	Sell	214,393 -50,217	-19%	-$1.11M	0.01%	833
2020 Q3	$4.76M	Buy	264,610 +46,536	+21%	+$964K	0.01%	767
2020 Q2	$5.54M	Sell	218,074 -14,636	-6%	-$315K	0.01%	711
2020 Q1	$4.27M	Buy	232,710 +16,766	+8%	+$326K	0.01%	737
2019 Q4	$4.76M	Buy	215,944 +193,681	+870%	+$3.9M	0.01%	815
2019 Q3	$320K	Hold	22,263	–	–	﹤0.01%	2014
2019 Q2	$351K	Hold	22,263	–	–	﹤0.01%	2004
2019 Q1	$326K	Hold	22,263	–	–	﹤0.01%	2010
2018 Q4	$238K	Buy	22,263 +4,554	+26%	+$59.9K	﹤0.01%	2147
2018 Q3	$270K	Buy	17,709 +722	+4%	+$10.5K	﹤0.01%	2201
2018 Q2	$208K	Buy	+16,987	New	+$213K	﹤0.01%	2341

Other funds holding DRNA

CAM

Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

VOYA Investment Management's DRNA Position: Q4 2021 in Review

VOYA Investment Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 151,085 shares — an estimated $3.05M sold.

VOYA Investment Management first reported a position in DRNA in Q2 2018 and held it in 14 quarters. The position peaked at $5.76M in Q2 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

VOYA Investment Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
VOYA Investment Management sold 151,085 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $3.05M.
VOYA Investment Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2018 and held it in 14 quarters.
VOYA Investment Management's Dicerna Pharmaceuticals, Inc. position peaked at $5.76M in Q2 2021.
1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on VOYA Investment Management's 13F filing for Q4 2021, filed 14 Feb 2022.